阿糖胞苷MA诱导化疗方案治疗老年AML的效果及预后  

Effect and prognosis of cytarabine MA induced chemotherapy regimen in the treatment of elderly AML

作　　者：晋红丽 张艳影 

机构地区：[1]辽宁省调兵山市铁法煤业集团总医院血液科,辽宁调兵山112700

出　　处：《临床和实验医学杂志》2016年第24期2443-2446,共4页Journal of Clinical and Experimental Medicine

摘　　要：目的探讨阿糖胞苷米托蒽醌+阿糖胞苷(MA)诱导化疗方案治疗老年急性髓性白血病(AML)的临床效果及其预后。方法对2010年1月至2014年1月接受治疗的67例老年AML患者的临床资料进行回顾性分析。根据患者治疗方法不同分为MA组和IA组[去甲氧柔红霉素(IDA)+阿糖胞苷(Ara-C)]。观察两组患者疗效及不良反应生存率的差异。结果 MA组总有效率58.3%显著高于IA组32.3%,差异有统计学意义(P<0.05)。两组重度骨髓抑制(Ⅲ级+Ⅳ级)的持续时间及其他不良反应发生率差异无统计学意义(P>0.05)。MA组平均生存时间为(13.76±4.21)个月显著长于IA组平均生存时间为(8.96±3.71)个月。MA组1年生存率为61.3%,显著高于IA组为38.1%(P<0.05)。结论对于老年AML患者,MA化疗方案的临床疗效优于IA组,且不良反应并无明显增加。MA诱导化疗方案具有显著改善老年AML患者的临床疗效,延长患者的生存期的优势。Objective Explore the clinical effect and prognosis of the cytarabine MA induced chemotherapy regimen for elderly AML.Methods A retrospective analysis in the clinical data of 67 cases of elderly patients with AML who received treatments in our hospital during January 2010 to January 2014.According to the difference of the treatment,67 cases of patients were divided into two groups：IA group and MA group.Results The total effective rate of MA group（58.3%） was significantly higher than that of IA group（32.3%）,and the difference was statistically significant（P〈0.05）.The main adverse reactions of the two groups were bone marrow suppression,and the difference was not statistically significant（P〉0.05）.The average survival time（13.76±4.21months） of MA group was significantly longer than that of the IA group（8.96±3.71 months）.1 year survival rate of MA group was 61.3%,and it was significantly higher than that of the IA group（38.1%）（P 0.05）.Conclusion MA＇s clinical curative effect for the elderly patients with AML is superior to the IA regimen.The adverse reactions had no obvious increase.MA induced chemotherapy regimens can dramatically improve the clinical benefit and prolong the lifetime.

关 键 词：急性髓性白血病 MA方案 IA方案 化疗 预后 

分 类 号：R733.71[医药卫生—肿瘤]